S. Al-Batran
13 Papers
1 Citations
S. Al-Batran is an academic researcher. The author has contributed to research in topics: Medicine & Precision medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Y.Y. Janjigian,S. Al-Batran,O. Wainberg,E. Van Cutsem,D. Molena,K. Muro,W. J. Hyung,L. Wyrwicz,D. Oh,T. Omori,M. Moehler,M. Garrido,S. Cunha Sousa Oliveira,M. Liberman,V. Castro Oliden,M. Bilici,J.F. Kurland,I. Xynos,H. Mann,J. Tabernero +19 more
TL;DR: The MATTERHORN study reports interim results of a Phase 3 trial evaluating durvalumab plus FLOT in resectable gastric and gastroesophageal junction cancer, showing pathological complete response in a subset of patients.
49
LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
K. Shitara,S.Y. Rha,L. Wyrwicz,T. Oshima,N. Karaseva,M. Osipov,H. Yasui,H. Yabusaki,S. Afanasyev,Y-K. Park,S. Al-Batran,T. Yoshikawa,P.E. Yanez Weber,Maxine G. Di Bartolomeo,S. Lonardi,C-S. Shih,Pooja Bhagia,Y-J. Bang +17 more
TL;DR: The KEYNOTE-585 study evaluated pembrolizumab plus chemotherapy versus chemotherapy alone as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer, with a focus on the third interim analysis of the phase III trial.
29
129O Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
D. Oh,Y.Y. Janjigian,S. Al-Batran,O. Wainberg,E. van Cutsem,D. Molena,K. Muro,W. J. Hyung,L. Wyrwicz,T. Omori,M. Moehler,M. Garrido,S. Cunha Sousa Oliveira,M. Liberman,V. Castro Oliden,M. Bilici,J. Kurland,I. Xynos,H. Mann,J. Tabernero +19 more
TL;DR: The MATTERHORN study reports a statistically significant improvement in pathological complete response (pCR) with the addition of durvalumab to perioperative FLOT therapy in resectable gastric and gastroesophageal junction cancer, with a tolerable safety profile.
5
1042P INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
A. Atmaca,D. W. Müller,T. Habibzada,M. Schaaf,J. Klagges,R. Eickhoff,E. Jäger,S. Al-Batran,T.O. Goetze +8 more
TL;DR: This study evaluates the feasibility and efficacy of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas, showing promising signals of efficacy and safety in 21 enrolled patients.
3
Oncology and public health
J.H. Zong,L. Eckert,L. Zhang,W.S. Dai,A.T. Cohen,Gary H. Lyman,A. Jirillo,M.P. Trojniak,S. Imbevaro,P. Rescigno,D. Pastorelli,A.C. Palozzo,J. Body,J. Pereira,H. Sleeboom,N. Maniadakis,E. Terpos,J. Finek,O. Gunther,G. Hechmati,T. Mossman,R. von Moos,M. Blanco Villalba,A. Pini,G. Streich,E. Molinas,J.R. Puyol,M.P. Bramajo,E.J. Batagelj,Ahmad S. Alfaar,Mohamed Kamal,Omneya Hassanain,M. Sabry,Sameera Ezzat,S. Abouelnaga,P. Das,Jayasri Basak,C.K. Bose,Arijit Mukhopadhyay,S. J. Mukhopadhyay,I. Duran,A. Mahmood,H. Hoefeler,H. Ghazal,D. Lueftner,M. Fink,A. Bahl,R. Wei,C. Atchison,T. Tanase,C. Hamada,Hirofumi Fujii,N. Nakayama,T. Denda,Tetsuji Takayama,T. Yoshino,A. Ohtsu,R. Zaim,W.K. Redekop,G.A.M.S. (Guus) van Dongen,R. de Bree,C.A. Uyl-de Groot,G.M. Bariani,A.C.R.C. Ferrari,P.M. Hoff,R. Arai,M. Precivale,R.P. Riechelmann,S-H Lee,L.C. Park,J.W. Lee,Sung Heon Kim,W. Chang,Young-Suk Park,Sabine Tejpar,T. Teague,J. Lake,Josep Tabernero,Johan Vansteenkiste,S. Vlassak,Fortunato Ciardiello,H.J. Conter,D. Conter,Robert A. Wolff,C. Reyes,S. Dacosta Byfield,A. Small,O. Mora,L. Marelli,P. Quadri,M. Tettamanti,C. Pedrazzani,M. Ghielmini,A. Baitar,F. van Fraeyenhove,A. Vandebroek,E. De Droogh,D. Galdermans,J. Mebis,D. Schrijvers,M. Laurent,E. Paillaud,M. Carvalho-Verlinde,P. Caillet,A. Le Thuaut,E. Liuu,S. Bastuji-Garin,S. Culine,F. Canouï-Poitrine,K. Chatterjee,S.K. Sarkar,S.K. Mondal,J. Goswami,B. Chatterjee,F. Schad,J. Axtner,A. Happe,A. Voigt,J. Gutsch,G. Spahn,C. Herbstreit,M. Debus,M. Kroez,H. Matthes,D-W. Ye,J. Guo,A. Zhou,Y. Huang,H. Li,Z. Hu,C. Fu,J. Liu,M. Irwin,J. Ma,S. Negrier,Y. Tang,Connie Chen,P. Bycott,K. Kim,J. Kim,H. Ryu,A. Bedikian,N. Papadopolous,P. Hwu,W. Hwu,S. Patel,A. Levaggi,G. Iacono,F. Poggio,C. Bighin,S. Giraudi,A. D'Alonzo,M. Lambertini,A. De Maria,P. Pronzato,L. Del Mastro,Jun Suk Kim,Y.J. Choi,R. Li,Y. Lou,L. Xiong,A. Gu,B. Han,Q. Dong,D. Debieuvre,C. Locher,I. Bourlaud,M. Zaegel,M. Le Poulain-Doubliez,J. Piquet,T. Collon,F. Martin,F. Blanchon,M. Grivaux,L.G. Fonseca,T.K. Takahashi,M.P. Mak,R. Barroso-Sousa,L. Testa,V. Petry Helena,R. De Paula Costa,M.S. Mano,V. Raina,Ajay Gogia,Svs Deo,B.K. Mohanti,Nootan Kumar Shukla,S. Banerjee,S. Gangopadhyay,G. Hebert,Florence Netzer,A. Fourcade,Michel Ducreux,E. Minvielle,François Lemare,F. Grude,J. Douillard,C. El Kouri,P. Donny,M. Urbanski,A. Chaslerie,S. Piau,H. Bourgeois,J. Metges,J. Pivette,R.W.F. van Leeuwen,D.H.S. Brundel,C. Neef,Ron H.J. Mathijssen,T. van Gelder,David M. Burger,F.G.A. Jansman,N. Cherny,R.E. Buschmann-Maiworm,W. Baumann,A. Zimmermann,S. Schmitz,U.R. Kleeberg,C.O. Ruiperez,M.L. Gomez,M. Molina-Garido,L.H. Martinez,A. Olaverri Hernandez,M. Muñoz Sanchez,JA Santiago Crespo,F. Lobo,A. Carrato,J. Feliu,J. Menis,A. Follador,Francesca Valent,C. Rossetto,M. Gaiardo,L. Gurrieri,E. Lugatti,S. Pizzolitto,V. Tozzi,G. Fasola,A. Kieszkowska-Grudny,M. Rucinska,E. Meszko,S. Nawrocki,R. Eckert,R. Curca,G. D'Addario,M.V. Karamouzis,G. Lanzetta,P. Martin Martorell,D. Mauri,S. Rauh,K. Tamas,G. Rosti,A. Costantini,M. Di Maio,E. Bria,D. Lorusso,L. De Fiore,D. Romeira,C.T. Carvalho,M. Proença,M. Alface,R. Cardiga,R. Ferreira,A. Leitão,C. Fonseca,F. Ceia,A.M. Martins,D. Pérez Callejo,R. Laporta,E. Almagro Casado,M. Palka,A. Ruiz-Valdepeñas,B. Cantos,C. Maximiano,M. Mendez Garcia,P. Ussetti,M. Provencio Pulla,A. Fani Pakdel,M. Rezazadeh,M. Naghiby Sustany,C. Guillen-Ponce,C. Ortega Ruiperez,F.K. Tauchert,R. Hofheinz,J. Quidde,N. Marschner,M. Hipp,M. Weber,H. Hoeffkes,E. Jaeger,S. Al-Batran,N. Jokhadze,M. Maglakelidze,R. Gagua,J.K. Chan,I. Amanam,T.K. Kiet,Nichole Young-Lin,D. Hoth,D.S. Kapp,B.J. Monk,D. Bertwistle,P. Anderson,M. Jofre-Bonet,E. Ferrat,J. Lebreton,S. Bercier,K. Veerabudun,Z. Brixi,C. Attali,C. Terret,S. Perrin +311 more
TL;DR: Compared to the overall cohort, major bleeding risk was higher in cancer patients who developed VTE, with the highest rates in patients with upper gastrointestinal cancer.
2